Author: Admin
Bioretec Ltd Inside information 26 October 2025 at 10.00 a.m. EEST TAMPERE, Finland, Oct. 27, 2025 /PRNewswire/ — On 12 September 2025, Bioretec Ltd (“Bioretec” or the “Company”), announced that the revised timeline of the planned commercialization of the DrillPin in the U.S. was then not expected to have a material effect on Bioretec’s financial targets published on 4 October 2024, and that Bioretec was assessing its overall commercialization strategy and pipeline, including the commercialization of the DrillPin in the U.S., and would provide an update by the end of 2025. The Company is currently in the process of assessing and updating…
Cross-specialty leader behind large-scale retina consolidation sees DentScribe’s AI turning SOAP notes into the operating system for growth. SAN JOSE, Calif., Oct. 27, 2025 /PRNewswire/ — DentScribe.ai, the agentic AI platform that transforms dental SOAP notes into real-time clinical checklists and practice growth signals, today announced that Dr. Mandeep S. Dhalla, MD, has invested in the company and joined as a Strategic Advisor.A board-certified ophthalmologist and internationally recognized vitreoretinal surgeon, Dr. Dhalla is a senior partner at Retina Group of Florida and a veteran of practice building, M&A, and technology adoption across specialty care. …
STOCKHOLM, Oct. 27, 2025 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for Leqembi® (lecanemab) for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer’s disease (early AD) who are apolipoprotein E ε4 (ApoE ε41) non-carriers or heterozygotes and who have confirmed amyloid pathology. LEQEMBI is the first treatment for early AD that targets an underlying cause of the disease, to be authorized in Canada. Leqembi selectively binds to soluble Aβ aggregates (protofibrilsi), as…
MARTINSVILLE, Va. — The cars of the drivers that vie for the title Sunday at Phoenix Raceway will sport yellow windshield banners and yellow spoilers.But only Kyle Larson’s uniform among the four drivers will carry this distinction: Champion.Larson is the only former Cup champion vying for the Cup title, but whether that makes a difference is debatable, as he faces three drivers who can point to their seasons and say they should be the favorite. Can Kyle Larson get into victory lane for another Cup title at Phoenix? Joe Gibbs Racing’s Denny Hamlin (most wins this year with six), JGR’s…
SHANGHAI and HONG KONG, Oct. 26, 2025 /PRNewswire/ — Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that the latest preclinical data of ATG-201 (CD19 x CD3 TCE) were presented in a Poster Presentation at the 2025 American College of Rheumatology (ACR) Annual Meeting, taking place from October 24th to October 29th in Chicago, IL, the United States. ATG-201 is a lead program developed using AnTenGager™, the company’s proprietary T-cell engager (TCE) platform which…
William Byron enjoyed a walk-off moment Sunday as he captured the NASCAR Cup Series victory at Martinsville Speedway to vault himself into a spot in the Championship 4.Byron, who wasn’t going to be able to make it to the final playoff round on points, nudged his way by Ryan Blaney and led the final 44 laps. The four drivers vying for the title next Sunday at Phoenix Raceway will come from two organizations: Hendrick Motorsports (Byron, Kyle Larson) and Joe Gibbs Racing (Denny Hamlin, Chase Briscoe). Eliminated from title contention were Team Penske drivers Joey Logano and Blaney, Hendrick’s Chase…
WASHINGTON, 26 de octubre de 2025 /PRNewswire-HISPANIC PR WIRE/ — La tercera temporada de la serie de investigación del estudio nominado por Peabody analiza de cerca algunos de los problemas de salud y bienestar que enfrentan las latinas estadounidenses de 40 a 59 años. 100 Latina Birthdays es un informe exhaustivo basado en Chicago y sus suburbios circundantes que se centra en las latinas en sus años de mediana edad. Aquí una muestra de los episodios publicados hasta el momento. Episodio 1: En la mediana edad, estas latinas finalmente comenzaron a pedir lo que sus cuerpos deseaban …
Long-term data shows significant and sustained blood pressure reductions in both office-based and 24-hour ambulatory blood pressure, reinforcing the durability, safety and effectiveness of the Symplicity™ blood pressure procedure in patients prescribed antihypertensive medications GALWAY, Ireland, Oct. 26, 2025 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced new, long-term results from its final report of the SPYRAL HTN-ON MED randomized clinical trial, showing that patients treated with the Symplicity™ Spyral renal denervation (RDN) procedure experienced significantly greater reductions in blood pressure compared to sham patients through three years. The data were presented as part…
Das Unternehmen nähert sich der Einreichung für die europäische CE-Kennzeichnung mit 150 eingeschriebenen Patienten und ist auf Kurs für die Markteinführung im Jahr 2027 HANGZHOU, China, 26. Oktober 2025 /PRNewswire/ — Venus Medtech (Hangzhou) Inc. (2500.HK, im Folgenden als „das Unternehmen” bezeichnet) gab heute den erfolgreichen Abschluss der Patientenrekrutierung für die Cardiovalve TARGET-Studie zum transkatheteralen Trikuspidalklappenersatz (TTVR) bekannt, an der insgesamt 150 Patienten teilnahmen. Der Abschluss der Registrierung stellt einen bedeutenden Meilenstein auf dem Weg zur europäischen Zulassung des Transcatheter Tricuspid Valve Replacement (TTVR)-Systems (Transkatheter-Trikuspidalklappenersatzsystems) von Cardiovalve dar, der führenden Lösung des Unternehmens zur Behandlung von Trikuspidalinsuffizienz. Nachdem die Registrierung nun abgeschlossen…
Novartis to acquire Avidity for USD 72.00 per share in cash for total equity value of approximately USD 12.0 billion Avidity expects to separate its early-stage precision cardiology programs into a new company (“SpinCo”) Closing expected in 1H2026 subject to completion of the separation of SpinCo from Avidity and other customary closing conditions SAN DIEGO, Oct. 26, 2025 /PRNewswire/ — Avidity Biosciences, Inc. (“Avidity”) (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (“AOCs™”) to profoundly improve people’s lives, today announced that it has entered into a definitive merger agreement with…